LakeShore Biopharma Co., Ltd (LSB)
LakeShore Biopharma Co., Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Beijing, CN. The stock last traded at $0.63, up 0.00% on the session, giving a market capitalisation of $25.8M. On trailing twelve-month figures it carries a trailing P/E of -4.49, a net margin of -16.3%. Its beta of 0.57 implies it has historically moved less than the broad market.
LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. The company maintains an international presence, conducting operations across China, the United States, Singapore, the United Arab Emirates, and the Philippines. Originally founded in 2002 and based in Beijing, China, the entity was known as YS Biopharma Co., Ltd until it officially changed its name to LakeShore Biopharma Co., Ltd in May 2024.
LakeShore Biopharma Co., Ltd is most often compared with the following Healthcare names: